Presented at the EORTC-NCI-AACR Symposium in Barcelona, the updated data from the Phase 1/2 RMC-GI-102 trial (NCT06445062) focused on 61 patients with treatment-naive metastatic pancreatic adenocarcinoma (mPDAC). As of a data cutoff on September 28, 2026, with a median follow-up of 18.3 months, the combination of daraxonrasib and chemotherapy demonstrated an overall response rate (ORR) of 60.7% (95% CI, 47.3%-72.9%). In 8.2% of these patients, tumors disappeared entirely on scans, defined as complete responses. The disease control rate, meaning the tumor shrank or stopped growing, was 90.2% (95% CI, 79.8%-96.3%).
The median progression-free survival (PFS)—the time until the cancer worsened—was 12.8 months (95% CI, 10.8-18.4), and the median duration of response was 11.1 months. An estimated 76.6% of patients were alive at the one-year mark (95% CI, 63.7%-85.4%). These figures are being compared by researchers to historical data from standard chemotherapy trials, where tumor shrinkage rates typically range from 23% to 42% and median overall survival is between 8.5 and 11.1 months. However, these historical figures come from different trials with different patient populations, meaning they do not constitute a direct statistical comparison to the current results.
Daraxonrasib, marketed as Rasonque, is an oral, RAS(ON) multi-selective, noncovalent, tri-complex inhibitor. RAS proteins act as molecular switches that signal cells to grow; mutated forms of these proteins drive the vast majority of pancreatic cancers. By binding RAS to another protein, cyclophilin A, daraxonrasib blocks the signaling pathways that promote cancer growth. Because it targets multiple forms of RAS rather than a single specific mutation, it has the potential to work across a broader range of pancreatic cancer cases.

The drug is already approved by the U.S. Food and Drug Administration (FDA) and the European Commission, but currently only for patients who have received at least one prior systemic therapy or are not candidates for multi-agent chemotherapy. This approval was based on the Phase 3 RASolute 302 trial, where daraxonrasib monotherapy showed a median overall survival of 13.2 months compared to 6.7 months with standard chemotherapy in previously treated patients. The new data, however, explores using the drug in the “first-line” setting—meaning as the very first treatment for newly diagnosed metastatic disease.
In the RMC-GI-102 trial, patients received 200 mg of daraxonrasib once daily, combined with gemcitabine and nab-paclitaxel, a standard chemotherapy regimen administered on days 1 and 15 of each cycle. The safety profile was consistent with known effects of the individual drugs. The most common side effects included rash, diarrhea, fatigue, and low blood counts, which are typical of chemotherapy but were managed with standard care. Approximately 5% of patients discontinued daraxonrasib due to side effects. No new safety signals were identified with the longer follow-up period.
Dr. Wungki Park, a medical oncologist at Memorial Sloan Kettering Cancer Center and a principal investigator on the study, described the results as “a potentially transformative advance in first-line treatment.” He noted that the emerging survival signal is meaningful, with nearly three-quarters of patients alive at one year. Dr. Elena Garralda, chair of the symposium and co-director of the clinical research program at the Vall d’Hebron Institute of Oncology in Spain, who was not involved in the study, stated that the results demonstrate that RAS-targeted drugs can be combined with existing treatments at the start of care to potentially achieve longer-lasting benefits.

Despite the promising numbers, medical experts emphasize that the study design has significant limitations. As an open-label, non-randomized, single-arm trial, every patient received the experimental combination. There was no group receiving chemotherapy alone to serve as a benchmark. Therefore, it is not yet possible to determine how much better the combination performs than standard care or if it definitively extends life. Additionally, the findings apply strictly to metastatic pancreatic cancer; while RAS mutations drive other cancers, such as certain lung and colorectal cancers, separate studies are required to test this combination in those diseases.
The trial was funded by Revolution Medicines, the developer of daraxonrasib. To address the limitations of the current data, researchers have launched a larger, randomized Phase 3 trial called RASolute 303 (NCT07491445). This study will directly compare the combination of daraxonrasib and chemotherapy against chemotherapy alone in patients with newly diagnosed metastatic pancreatic cancer. The results of this pivotal trial will be essential to determine whether daraxonrasib should become a standard first-line treatment option for this aggressive disease.



